drugset / Trial / NCT05038839
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Cabozantinib and pamiparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2022-02-09
- Primary completion
- 2026-05-05
- Completion
- 2026-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | Oral |
| Subject | Pamiparib | Small molecule | — | Oral |